|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
價值評估 |
盈利(現時/預測)
-1.14/-0.78
|
企業價值
278.47M
|
資產負債 |
每股賬面淨值
-1.06
|
現金流量 |
現金流量率
--
|
損益表 |
收益
146.03M
|
每股收益
1.17
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2024/10/31 18:38 EDT
同行比較之報價最少15分鐘延遲
業務概覽
|
|||
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuselarge B-cell lymphoma. The company derives its revenue from United States. |